New Mexico is currently home to 423 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Albuquerque, Santa Fe, Las Cruces and Farmington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)
NCT05465044
Recruiting
In this pragmatic clinical trial, which will dovetail with Veterans' routine outpatient dialysis clinic visits in six VA medical centers, the investigators will study 252 Veterans with kidney disease who need to start dialysis treatment. If a Veteran is eligible for the study by making enough residual urine, he/she will have a 50% chance to be offered the usual three-times-per-week dialysis vs. twice-per-week dialysis that is gradually increased to three-times per- week over one year. The invest... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/28/2023
Locations: New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico
Conditions: Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD), Dialysis Dependency
Register for Updates
Suicide in Urban Natives: Detection and Networks to Combat Events
NCT03136094
Recruiting
This study compares the effectiveness of a program to detect and manage suicide risk among American-Indian and Alaska Native (AI/AN) youth. Half of the participants will receive caring text messages to reduce suicidal thoughts, attempts, and hospitalizations and to increase engagement, social connectedness, and resilience in at-risk youth. The other half will receive usual care that does not include the caring text messages.
Gender:
All
Ages:
Between 18 years and 34 years
Trial Updated:
04/21/2023
Locations: First Nations Community HealthSource, Albuquerque, New Mexico
Conditions: Suicide Prevention
Register for Updates
Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome
NCT04717427
Recruiting
Individuals with Sturge-Weber Syndrome (SWS) sometimes have brain involvement which can result in seizures, stroke-like episodes and neurologic deficits. The purpose of this study is to integrate longitudinal clinical data, radiological data, and blood biomarkers of Sturge-Weber syndrome patients. The research aims are: To integrate longitudinal clinical data, radiological data, and blood biomarkers of Sturge-Weber syndrome patients. Identify plasma and imaging biomarkers sensitive to exacerba... Read More
Gender:
All
Ages:
All
Trial Updated:
04/20/2023
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Sturge-Weber Syndrome
Register for Updates
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Christus St. Vincent Regional Cancer Center, Santa Fe, New Mexico
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
NCT04136002
Recruiting
The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population.
Gender:
All
Ages:
Between 45 years and 84 years
Trial Updated:
04/04/2023
Locations: Lovelace Scientific Resources, Inc., Albuquerque, New Mexico
Conditions: Colorectal Cancer
Register for Updates
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: New Mexico Cancer Care Alliance, Albuquerque, New Mexico
Conditions: Breast Cancer
Register for Updates
Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites
NCT04288921
Recruiting
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx Influenza A/B + RSV Test at Point of Care Testing Sites
Gender:
All
Ages:
All
Trial Updated:
03/10/2023
Locations: Southwest Care, Santa Fe, New Mexico
Conditions: Influenza, Human, Respiratory Syncytial Virus Infections
Register for Updates
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
NCT05364645
Recruiting
This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not responded to previous RET directed therapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selpercatinib may st... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
NCT04266197
Recruiting
The objectives of this study are to evaluate the effects of RT234 on exercise parameters assessed by a specialized exercise test (Cardiopulmonary Exercise Test or CPET) in patients with pulmonary arterial hypertension (PAH).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/09/2023
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Anti-inflammatory Actions of Osteopathic Manipulative Treatment
NCT04177264
Recruiting
This study evaluates the hypothesis that osteopathic manipulative treatment (OMT) and non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) elicit anti-inflammatory actions through activation of the parasympathetic nervous system. In a cross-over design, research participants will be subjected to various combinations of OMT, taVNS, or sham interventions during four study sessions, that are at least one month apart. During each study session research participants will undergo OMT... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2023
Locations: Burrell College of Osteopathic Medicine, Las Cruces, New Mexico
Conditions: Inflammation
Register for Updates
TruGraf® Long-term Clinical Outcomes Study
NCT04491552
Recruiting
This is a prospective, multi-center, observational study. Subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at study enrollment and thereafter every 3 months. In addition subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at any time there is a clinical suspicion of acute rejection. Data collection for the primary objective extends over a 2-year period.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: University of New Mexico Health Sciences Center, Albuquerque, New Mexico
Conditions: Kidney Transplant Rejection
Register for Updates
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates